Trial Profile
Proof-of-concept study of agomelatine (NRT 34) for the treatment of children with autism spectrum disorders.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2012
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- 20 Aug 2012 New trial record